Publications

Export 11 results:
Sort by: Author Title Type [ Year  (Desc)]
2017
A El Shafei, M. Eltemamy, Y Nyame, and H. Arora, "MP70-13 CRYOSURGICAL ABLATION OF THE PROSTATE: LOCAL DISEASE CONTROL FOR INTERMEDIATE/HIGH-GRADE GLEASON PROSTATE …", Journal of Uology, vol. 197, issue 4, pp. 940, 2017.
Edward Bass, Y. Shanmugabavan, Shanmugabavan, and Mohamed Eltemamy, "MP70-15 INTRA-PROSTATIC PRX302 FOCAL THERAPY IN TREATING CLINICALLY SIGNIFICANT LOW-INTERMEDIATE PROSTATE CANCER: AN OPEN LABEL, PROOF-OF-CONCEPT STUDY", Journal of Urology, vol. 197, issue 4, pp. 940-941, 2017.
A El Shafei, Y Nyame, H. Arora, and M. Eltemamy, "PD28-09 DOES MRI-FUSION PROSTATE BIOPSY IMPROVE RISK RECLASSIFICATION FOR PATIENTS WITH PROSTATE CANCER ON ACTIVE ", Journal of Urology, vol. 197, issue 4, pp. 521, 2017.
Mohamed Eltemamy, mahmoud abdel hakim, A. el-Feel, and O. Abdel-Razzak, "PD73-10 COMPARISON BETWEEN LAPAROENDOSCOPIC SINGLE SITE NEPHRECTOMY AND CONVENTIONAL LAPAROSCOPIC NEPHRECTOMY: A RANDOMIZED CONTROL SINGLE INSTITUTION EXPERIENCE", Journal of Uology, vol. 197, issue 4, pp. 1370-1371, 2017.
2016
Eltemamy, M. M., M. S. Leapman, J. E. Cowan, A. Westphalen, K. Shinohara, and P. R. Carroll, "Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance.", The Journal of urology, vol. 196, issue 3, pp. 727-33, 2016 Sep. Abstract

PURPOSE: The growth potential of low grade prostate cancer is unknown and yet it is potentially impactful for the practice of active surveillance. We evaluated the incidence, growth dynamics and clinical significance of changes in prostate lesions on serial transrectal ultrasound among a large cohort of men with prostate cancer managed by active surveillance.

MATERIALS AND METHODS: This retrospective study included men with prostate cancer treated with active surveillance at UCSF (University of California-San Francisco) from 2000 to 2014 who underwent a minimum of 2 transrectal ultrasound studies. Study inclusion criteria were prostate specific antigen 20 ng/ml or less, clinical stage T2 or less and biopsy Gleason grade 3 + 4 or less. Progression end points included an increase in imaging stage, a 50% or greater increase in volume and an increase in the number of sites (sextants) with apparent lesions. The relationship between transrectal ultrasound progression and biopsy Gleason upgrade was assessed by univariate and multivariate logistic regression models.

RESULTS: The 875 identified patients underwent a median of 5 transrectal ultrasound studies (IQR 3-8). Median followup was 49 months (IQR 27-81). Of the patients 345 (39%) progressed on serial transrectal ultrasound, including 51 by size, 265 by the number of lesion sites and 279 by stage. Median time to progression was 14 months. Transrectal ultrasound progression was independently associated with biopsy upgrade (OR 1.8, 95% CI 1.3-2.5, p <0.01).

CONCLUSIONS: Local progression on transrectal ultrasound was associated with Gleason upgrade at biopsy. These results suggest that stable imaging findings on transrectal ultrasound may allow for increased intervals between biopsies among men on active surveillance. A prospective study is required to evaluate the usefulness of such a practice.

Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.
Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.
Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.
Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.
Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.
Michael S. Leapman, J. E. Cowan, G. Roberge, and M. M. Eltemamy, "External validation of a prognostic Gleason grade classification system.", Journal of Clinical Oncology, vol. 34, pp. 123-123, 2016.